The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG announced a collaboration to utilize Protagen’s Cancer Immunotherapy Array to identify biomarkers that predict therapeutic response and the incidence of immune-related adverse events (irAEs) in urothelial carcinoma patients treated with checkpoint inhibitors.

ADC Biotechnology (ADC Bio) predicts that the next crucial phase of innovation to optimise and streamline production processes of ADCs will be designed at the clinical development stage by specialist, ADC focused service providers.

IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few contract development and manufacturing organisations (CDMO) to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.

Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, and ERS Genomics have extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology.

Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.

Roche Holding AG (ROG.EB) said that a phase 3 IMpower150 study showed an improvement in the treatment of advanced lung cancer with the use of Tecentriq.